‘Most powerful weight-loss jab ever’ that outperforms Wegovy and Mounjaro shows insane results

A new weight-loss drug has shown some promising results in a major trial and is said to be outperforming some of the biggest players in the game.

Retatrutide is an experimental once-weekly injectable medication developed by Eli Lilly that is currently undergoing Phase 3 clinical trials for obesity and type 2 diabetes.

Often dubbed the 'triple-G' or 'Godzilla' of weight loss, it targets three different hormone receptors to dramatically suppress appetite and increase fat burning, while current medications like Wegovy and Mounjaro target one or two.

In a major trial involving more than 2,300 overweight adults, people taking the highest dose lost an average of 28.3 percent of their body weight. Some patients lost around five stone.

What does retatrutide actually do?

Retatrutide is an experimental once-weekly injectable medication developed by Eli Lilly (Retatrutide)

The drug is made by Eli Lilly and Company and like current treatments, it reduces appetite and slows digestion.

But it also helps the body burn extra calories, leading researchers to describe it as 'exercise in a jab'.

Almost half of patients taking the top dose lost at least 30 percent of their body weight — results normally only seen with weight-loss surgery.

Patients also saw major improvements in blood pressure, cholesterol and waist size.

Dr Kenneth Custer, Lilly's executive vice president, said: "The 12mg dose delivered a level of weight loss long associated with bariatric surgery."

Dr Simon Cork, from Anglia Ruskin University, said 'these early results are incredibly promising' (Getty Stock Images)

Professor Ania Jastreboff, lead investigator on the trial at Yale School of Medicine, added: "Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease.

"It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30 percent of their body weight over two years.

"Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures.

"For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory."

Retatrutide side effects

"As with other medicines in the incretin-based drug class, retatrutide is associated with a range of side effects, the majority of which relate to the gastrointestinal system," Bolt Pharmacy explain.

In Phase 2 trial data, the most commonly reported adverse effects included:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Decreased appetite

"Retatrutide is not yet available in the UK and has not been approved for use by any regulatory bodies – it is still undergoing clinical trials to assess its safety and effectiveness," Dr Clair Grainger, from Superdrug Online Doctor, said.

LADbible Group has contacted Wegovy and Mounjaro for comment.